WO2006062871A3 - Materials and methods for minimally-invasive administration of a cell-containing flowable composition - Google Patents

Materials and methods for minimally-invasive administration of a cell-containing flowable composition Download PDF

Info

Publication number
WO2006062871A3
WO2006062871A3 PCT/US2005/043844 US2005043844W WO2006062871A3 WO 2006062871 A3 WO2006062871 A3 WO 2006062871A3 US 2005043844 W US2005043844 W US 2005043844W WO 2006062871 A3 WO2006062871 A3 WO 2006062871A3
Authority
WO
WIPO (PCT)
Prior art keywords
minimally
cell
flowable composition
materials
methods
Prior art date
Application number
PCT/US2005/043844
Other languages
French (fr)
Other versions
WO2006062871A9 (en
WO2006062871A2 (en
Inventor
Helen Marie Nugent
Elazer Edelman
Steve Bollinger
Original Assignee
Pervasis Therapeutics Inc
Helen Marie Nugent
Elazer Edelman
Steve Bollinger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pervasis Therapeutics Inc, Helen Marie Nugent, Elazer Edelman, Steve Bollinger filed Critical Pervasis Therapeutics Inc
Priority to EP05848586A priority Critical patent/EP1824526B1/en
Priority to JP2007545539A priority patent/JP5674256B2/en
Priority to AT05848586T priority patent/ATE450276T1/en
Priority to DE602005018103T priority patent/DE602005018103D1/en
Priority to CA2589588A priority patent/CA2589588C/en
Priority to AU2005314312A priority patent/AU2005314312B2/en
Priority to CN200580042372XA priority patent/CN101076360B/en
Priority to US11/792,284 priority patent/US20080118561A1/en
Priority claimed from PCT/US2005/044090 external-priority patent/WO2006062962A2/en
Priority claimed from PCT/US2005/043967 external-priority patent/WO2006062909A2/en
Publication of WO2006062871A2 publication Critical patent/WO2006062871A2/en
Publication of WO2006062871A3 publication Critical patent/WO2006062871A3/en
Priority to IL183784A priority patent/IL183784A/en
Priority to HK08101924.1A priority patent/HK1112428A1/en
Publication of WO2006062871A9 publication Critical patent/WO2006062871A9/en
Priority to US12/880,931 priority patent/US20110002973A1/en
Priority to IL209574A priority patent/IL209574A/en
Priority to AU2010249280A priority patent/AU2010249280B2/en
Priority to US13/467,180 priority patent/US20130052166A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3886—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells comprising two or more cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3808—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions

Abstract

The disclosed invention is based on the discovery that a cell-based therapy can be used to treat, ameliorate, manage and/or reduce the progression of clinical sequelae associated with vascular interventions or cardiovascular diseases, particularly occlusive thrombosis, restenosis, intimal hyperplasia, inflammation and vasodilation. The invention further benefits from the additional discovery that a heretofore undescribed implantable flowable composition is capable of sustaining a confluent population of sufficiently viable cells which can be effectively administered via a minimally-invasive surgical procedure without diminishing the clinical effectiveness or the viability of the cells. The disclosed invention can be used to treat vasculature as well as non-vascular tubular structures such as a fallopian tube.
PCT/US2005/043844 2004-12-08 2005-12-06 Materials and methods for minimally-invasive administration of a cell-containing flowable composition WO2006062871A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
EP05848586A EP1824526B1 (en) 2004-12-08 2005-12-06 Materials and methods for minimally-invasive administration of a cell-containing flowable composition
JP2007545539A JP5674256B2 (en) 2004-12-08 2005-12-06 Materials and methods for minimally invasive administration of cell-containing flowable compositions
AT05848586T ATE450276T1 (en) 2004-12-08 2005-12-06 MATERIALS AND METHODS FOR MINIMALLY INVASIVE DELIVERY OF A CELL-CONTAINING FLOWABLE COMPOSITION
DE602005018103T DE602005018103D1 (en) 2004-12-08 2005-12-06 MATERIALS AND METHODS FOR MINIMALLY INVASIVE DELIVERY OF A CELL-CONTAINING FLUID COMPOSITION
CA2589588A CA2589588C (en) 2004-12-08 2005-12-06 Materials and methods for minimally-invasive administration of a cell-containing flowable composition
AU2005314312A AU2005314312B2 (en) 2004-12-08 2005-12-06 Materials and methods for minimally-invasive administration of a cell-containing flowable composition
CN200580042372XA CN101076360B (en) 2004-12-08 2005-12-06 Materials and methods for minimally-invasive administration of a cell-containing flowable composition
US11/792,284 US20080118561A1 (en) 2004-12-08 2005-12-06 Materials and Methods for Minimally-Invasive Administration of a Cell-Containing Flowable Composition
IL183784A IL183784A (en) 2004-12-08 2007-06-07 Materials for minimally-invasive administration of a cell-containing flowable composition
HK08101924.1A HK1112428A1 (en) 2004-12-08 2008-02-21 Materials and methods for minimally-invasive administration of a cell- containing flowable composition
US12/880,931 US20110002973A1 (en) 2004-12-08 2010-09-13 Materials and methods for minimally-invasive administration of a cell-containing flowable composition
IL209574A IL209574A (en) 2004-12-08 2010-11-25 Materials for minimally-invasive administration of a cell-containing flowable composition
AU2010249280A AU2010249280B2 (en) 2004-12-08 2010-12-10 Materials and methods for minimally-invasive administration of a cell-containing flowable composition
US13/467,180 US20130052166A1 (en) 2004-12-08 2012-05-09 Materials and methods for minimally-invasive administration of a cell-containing flowable composition

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US63415504P 2004-12-08 2004-12-08
US60/634,155 2004-12-08
US66385905P 2005-03-21 2005-03-21
US60/663,859 2005-03-21
US68205405P 2005-05-18 2005-05-18
US60/682,054 2005-05-18
PCT/US2005/043967 WO2006062909A2 (en) 2004-12-08 2005-12-06 Methods and compositions for enhancing vascular access
USPCT/US2005/043967 2005-12-06
USPCT/US2005/044090 2005-12-06
PCT/US2005/044090 WO2006062962A2 (en) 2004-12-08 2005-12-06 Materials and methods for treating and managing plaque disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/880,931 Continuation US20110002973A1 (en) 2004-12-08 2010-09-13 Materials and methods for minimally-invasive administration of a cell-containing flowable composition

Publications (3)

Publication Number Publication Date
WO2006062871A2 WO2006062871A2 (en) 2006-06-15
WO2006062871A3 true WO2006062871A3 (en) 2006-09-28
WO2006062871A9 WO2006062871A9 (en) 2009-01-22

Family

ID=36293671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/043844 WO2006062871A2 (en) 2004-12-08 2005-12-06 Materials and methods for minimally-invasive administration of a cell-containing flowable composition

Country Status (1)

Country Link
WO (1) WO2006062871A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE470701T1 (en) 2005-04-21 2010-06-15 Massachusetts Inst Technology MATERIALS AND METHODS FOR ALTERING AN IMMUNE RESPONSE TO EXOGENE AND ENDOGENE IMMUNOGENES, INCLUDING GENIDENTIC AND NON-GENIDENTIC CELLS, TISSUES OR ORGANS
CN101878757A (en) 2005-06-21 2010-11-10 渗透治疗有限公司 Be used to strengthen the method and composition of vascular access
CN103230414A (en) * 2006-11-07 2013-08-07 夏尔再生医学公司 Materials and methods for treating and managing angiogenesis-mediated diseases
WO2008057590A2 (en) * 2006-11-07 2008-05-15 Pervasis Therapeutics, Inc. Methods and compositions for modulating tissue modeling
WO2008086228A2 (en) 2007-01-04 2008-07-17 University Of Washington Arrays and methods for guided cell patterning
WO2009020650A2 (en) * 2007-08-08 2009-02-12 Pervasis Therapeutics, Inc. Materials and methods for treating and managing wounds and the effects of trauma
EP2207558A1 (en) 2007-11-06 2010-07-21 Massachusetts Institute of Technology Tissue-engineered endothelial and epithelial implants differentially and synergistically regulate tissue repair
MX2010014077A (en) * 2008-06-26 2011-04-05 Kanemaru Shinichi Agent for regenerating tympanic membrane or external auditory canal.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010036451A1 (en) * 2000-03-13 2001-11-01 Goupil Dennis W. Embolic compositions
US20020090398A1 (en) * 1999-11-16 2002-07-11 Atrix Laboratories, Inc. Biodegradable polymer composition
US20030163192A1 (en) * 2000-11-15 2003-08-28 George Wallace Methods for vascular reconstruction of diseased arteries
US6723131B2 (en) * 2001-02-28 2004-04-20 The Cleveland Clinic Foundation Composite bone marrow graft material with method and kit

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020090398A1 (en) * 1999-11-16 2002-07-11 Atrix Laboratories, Inc. Biodegradable polymer composition
US20010036451A1 (en) * 2000-03-13 2001-11-01 Goupil Dennis W. Embolic compositions
US20030163192A1 (en) * 2000-11-15 2003-08-28 George Wallace Methods for vascular reconstruction of diseased arteries
US6723131B2 (en) * 2001-02-28 2004-04-20 The Cleveland Clinic Foundation Composite bone marrow graft material with method and kit

Also Published As

Publication number Publication date
WO2006062871A9 (en) 2009-01-22
WO2006062871A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
WO2006062871A3 (en) Materials and methods for minimally-invasive administration of a cell-containing flowable composition
Morris et al. Cardiovascular effects of exposure to cigarette smoke and electronic cigarettes: clinical perspectives from the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology
Versari et al. The importance of reendothelialization after arterial injury
WO2006124398A3 (en) Methods and systems for delivering substances into luminal walls
WO2008087488A3 (en) Expandable medical device for the treatment and prevention of cardiovascular diseases
Bao et al. Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats
MX2020002648A (en) Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3).
Bai et al. Endothelial damage and stem cell repair in atherosclerosis
Maegdefessel et al. MicroRNA-29b regulation of abdominal aortic aneurysm development
NZ606825A (en) Methods and compositions for treating complement-associated disorders
MY167123A (en) Conveniently implantable sustained release drug compositions
ECSP066534A (en) DOSAGE FORMS OF CONTROLLED OXYCODONE, ORALS, ONCE A DAY
Zhang et al. Ginsenoside Rb1 attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of the JNK and p38 signaling pathways
EP1562669A4 (en) Device with an expandable portion for drug release
WO2006034207A3 (en) Use of gsk3 inhibitors in combination with radiation therapies
WO2007098443A3 (en) Apparatuses and techniques for bioactive drug delivery in the prostate gland
SG155053A1 (en) Method of obtaining viable human liver cells, including hepatic stem/progenitor cells
WO2006085115A3 (en) Therapeutic uses of tomato extracts
Osende et al. Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist
DK1526840T3 (en) Nanoparticles for DNA administration to a target organ
Jackson et al. Antithrombotic phosphoinositide 3‐kinase β inhibitors in humans: a ‘shear’delight!
WO2011089618A3 (en) Drug-eluting insert able medical device for treating acute myocardial infarction, thrombus containing lesions and saphenous- vein graft lesions
Wenjing et al. The role of IL-1β in aortic aneurysm
He et al. Dihydroartemisinin ameliorates balloon injury‐induced neointimal formation in rats
Hermann et al. To the heart of the matter: coxibs, smoking, and cardiovascular risk

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2589588

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11792284

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007545539

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580042372.X

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005848586

Country of ref document: EP

Ref document number: 2005314312

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2361/KOLNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005314312

Country of ref document: AU

Date of ref document: 20051206

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005314312

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005848586

Country of ref document: EP